science2 publishers
One missed hand-opening endpoint costs Novartis 2.5 times the Avidity purchase price
Artisan Partners' David Samra is telling Novartis's chairman to rebuild the team that does its deals, after a week of three Phase III setbacks in which one of the drugs actually met its primary endpoint.
Reality
- Evidence66
- Adoption22
- Hype gap+28
- Incentives68
- Confidence62